ClinicalTrialsFinder

Refractory Primary Central Nervous System Lymphoma Clinical Trials in Seattle, Washington

1 recruitingSeattle, Washington

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078